GLP-1 medications are not approved to treat the insulin deficiency caused by type 1 diabetes, although some adults with type 1 diabetes may use them for obesity management under close medical supervision.
The 2026 American Diabetes Association Standards of Care recommend considering obesity-management treatment, including GLP-1 receptor agonist-based therapy, for adults with type 1 diabetes and obesity. The recommendation applies to a BMI of at least 30, or at least 27.5 for Asian American adults. Treatment should involve shared decision-making with a diabetes specialist.
GLP-1 medicines do not replace insulin. Type 1 diabetes involves absent or near-absent beta-cell function, so insulin remains necessary.
GLP-1 Medications and Type 1 Diabetes at a Glance
| Question | Practical answer |
|---|---|
| Can someone with type 1 diabetes take a GLP-1? | Sometimes, particularly when obesity is also present |
| Does it replace basal or mealtime insulin? | No. Insulin remains essential |
| Is Ozempic approved to treat type 1 diabetes? | No. Ozempic is approved for adults with type 2 diabetes and certain related cardiovascular or kidney indications |
| Can Wegovy or Zepbound be considered? | They may be considered for eligible obesity treatment, with closer monitoring in type 1 diabetes |
| What are the main concerns? | Hypoglycemia, lower insulin requirements, ketosis, vomiting, dehydration and delayed stomach emptying |
| Who should decide? | An endocrinologist or diabetes specialist, not the patient alone |
When Might a Person With Type 1 Diabetes Be Prescribed a GLP-1?
Adults with type 1 diabetes may be prescribed a GLP-1 medication when obesity is also present and the clinician determines that the potential benefits outweigh the risks.
A clinician may consider treatment when obesity occurs alongside conditions such as:
- Obstructive sleep apnea
- Cardiovascular disease
- Metabolic dysfunction-associated steatotic liver disease
- Other weight-related health risks
This use is different from taking semaglutide or tirzepatide as a routine blood glucose treatment for type 1 diabetes. The ADA continues to identify insulin as essential because type 1 diabetes causes absent or near-absent beta-cell function.
Are Ozempic, Wegovy and Zepbound Approved for Type 1 Diabetes?
No. None of these medications should replace insulin.
Ozempic, semaglutide, is FDA-approved to improve blood glucose control in adults with type 2 diabetes. It also has cardiovascular and kidney indications for certain people with type 2 diabetes. The FDA label does not list type 1 diabetes as an indication.
Wegovy, semaglutide, is FDA-approved for chronic weight management in people who meet obesity or overweight criteria. It also has certain cardiovascular-risk indications. The FDA label states that use in people with type 1 diabetes, or in combination with insulin, has not been evaluated.
Zepbound, tirzepatide, is a dual GIP and GLP-1 receptor agonist approved for chronic weight management in eligible adults with obesity or overweight. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity. It is not a treatment for type 1 diabetes itself.
Whether someone with type 1 diabetes qualifies for an obesity medication depends on BMI, other health conditions, contraindications, insurance rules and the clinician's assessment.
Why Is GLP-1 Treatment More Complicated in Type 1 Diabetes?
GLP-1 medicines can reduce appetite, slow stomach emptying and lower food intake. Those effects may reduce insulin requirements, but they can also create problems when insulin is cut too much or meals become inadequate.
In liraglutide trials involving people with type 1 diabetes, the highest dose produced an approximately 0.4 percentage-point reduction in A1C and about 5 kg of weight loss. Hypoglycemia increased by approximately 20% to 30% across doses. Hyperglycemia with ketosis occurred about twice as often at the highest dose as it did with placebo.
The 2026 ADA guidance warns against transferring dose-escalation schedules from type 2 diabetes directly to type 1 diabetes. Titration may need to be slower, with close review of insulin requirements, glucose trends and ketone levels.
What Are the Main Risks for People With Type 1 Diabetes?
Hypoglycemia
GLP-1 treatment can raise the risk of low blood sugar when combined with insulin. The risk may be higher when appetite and carbohydrate intake fall but insulin doses do not change appropriately.
The FDA labels for semaglutide and tirzepatide warn that combining these medicines with insulin can increase hypoglycemia risk.
Ketosis and Diabetic Ketoacidosis
Cutting insulin too much, eating very little, becoming dehydrated or vomiting can promote ketone production. People with type 1 diabetes cannot safely stop insulin.
The ADA advises particular caution for people with a recent episode of diabetic ketoacidosis or euglycemic ketoacidosis. A history of hypoglycemia unawareness or serious gastroparesis may also make GLP-1 treatment unsuitable.
Gastrointestinal Side Effects
Nausea, vomiting, diarrhea, constipation and abdominal discomfort are common adverse effects. Severe vomiting or diarrhea can cause dehydration and make glucose and ketone management harder. Wegovy is not recommended for people with severe gastroparesis.
Other Contraindications and Precautions
Semaglutide and tirzepatide products carry boxed warnings related to thyroid C-cell tumors. They should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Before prescribing, clinicians also consider pancreatitis, gallbladder disease, diabetic retinopathy, pregnancy and severe gastrointestinal disease.
How Can a Person With Type 1 Diabetes Use a GLP-1 More Safely?
If an endocrinologist prescribes a GLP-1-based medicine, the treatment plan should usually include:
- Continue basal insulin. Do not stop insulin or make large dose reductions without medical instructions.
- Use continuous glucose monitoring when available. Glucose trends can help identify hypoglycemia as appetite and insulin needs change.
- Check ketones during illness or reduced food intake. Ketone testing is especially important with nausea, vomiting, persistent high glucose or suspected insulin deficiency.
- Maintain adequate carbohydrate and fluid intake. Appetite suppression should not lead to prolonged fasting.
- Review insulin pump or automated insulin delivery settings. Insulin-to-carbohydrate ratios, correction factors and basal settings may need adjustment.
- Follow a diabetes sick-day plan. Seek urgent medical care for suspected ketoacidosis, repeated vomiting, inability to keep fluids down or severe breathing problems.
Bottom Line
Some people with type 1 diabetes can take a GLP-1 medication, especially when obesity is also present. The decision requires individualized review by an endocrinologist or another diabetes specialist.
GLP-1 treatment may help with weight management and reduce insulin requirements. It can also raise the risk of hypoglycemia and ketosis if insulin, food intake and ketone monitoring are not managed carefully.
Do not use Ozempic, Wegovy, Zepbound or a compounded GLP-1 product to replace insulin or change insulin doses without guidance from your diabetes care team.